α-Tocopheryl succinate induces apoptosis in erbB2-expressing breast cancer cell via NF-κB pathway

Acta Pharmacologica Sinica

Volumn 31, Issue 12, 2010, Pages 1604-1610

  Wang, Xiu Fang ^a   Xie, Ying ^a   Wang, Hong Gang ^a,b   Zhang, Yuan ^a   Duan, Xiao Cui ^a   Lu, Zhan Jun ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b HENAN UNIVERSITY   (China)

Author keywords

TOS; apoptosis; breast cancer; erbB2; hrTRAIL; NF B

Indexed keywords

ALPHA TOCOPHEROL SUCCINATE; CASPASE; CASPASE 3; CASPASE 8; CELL PROTEIN; CELLULAR INHIBITOR OF APOPTOSIS PROTEIN 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLICE INHIBITORY PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOCORTIN 5; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; COLORIMETRY; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE ACTIVATION; HUMAN; HUMAN TISSUE; INHIBITION KINETICS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ALPHA-TOCOPHEROL; ANTIOXIDANTS; APOPTOSIS; BREAST NEOPLASMS; CASPASES; CELL LINE, TUMOR; FEMALE; HUMANS; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78649951793     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2010.171     Document Type: Article

References (29)

1. Roskoski R. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun 2004;319:1-11.
2. Jarvinen TA, Liu ET. Simultaneous amplifcation of Her (ErbB2) and topoisomerase IIα (TOP2A) genes in combination therapy in cancer. Curr cancer drug targets 2006;6:579-602.
3. Ward SG, Finan P. Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents. Curr Opin Pharmacol 2003;3:426-34. (Pubitemid 36908947)
4. Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL, et al. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 2003;17:590-603.
5. Kane LP, Shapiro VS, Stokoe D, Weiss A. Induction of NF-κB by the Akt/PDK kinase. Curr Biol 1999;9:601-4.
6. Shukla S, Maclennan GT, Marengo SR, Resnick MI, Gupta S. Constitutive activation of PI3K-Akt and NF-kappaB during prostate cancer progression in autochthonous transgenic mouse model. Prostate 2005;64:224-39.
7. La Casse EC, Baird S, Korneluk RG, MacKenzie AE. The inhibitors of apoptosis protein (IAPs) and their emerging role in cancer. Oncogene 1998;17:3247-59.
8. Kim KM, Lee YJ. Amiloride augments TRAIL-induced apoptotic death by inhibiting phosphorylation of kinases and phosphatases associated with the P13KAkt pathway. Oncogene 2005;24:355-66.
9. Neuzil J, Tomasetti M, Mellick AS, Alleva R, Salvatore BA, Birringer M, et al. Vitamin E analogues: A new class of inducers of apoptosis with selective anti-cancer effect. Curr Cancer Drug Targets 2004;4:267-84.
10. Wang XF, Witting PK, Salvatore BA, Neuzil J. Vitamin E analogs trigger apoptosis in HER2/erbB2-overexpressing breast cancer cells by signaling via the mitochondrial pathway. Biochem Biophys Res Commun 2005;326:282-9.
11. Gliniak B, Le T. Tumor necrosis factor-related apoptosis-inducing ligand's anti-tumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. Cancer Res 1999;59:6153-8.
12. Matsuzaki H, Schmied BM, Ulrich A, Standop J, Scheider MB, Batra SK, et al. Combination of tumour necrosis factor-related apoptosisinducing ligand (TRAIL) and actinomycin D induces apoptosis even in TRAIL-resistant human pancreatic cancer cells. Clin Cancer Res 2001;7:407-14.
13. Bernard D, Quatannens B, Vandenbunder B, Abbadie C. Rel/NF-κB transcription factors protect against tumour necrosis factor (TNF) - related apoptosis-inducing ligand (TRAIL)-induced apoptosis by upregulating the TRAIL decoy receptor DcR1. J Biol Chem 2001;276:27322-8.
14. Tomasetti M, Rippo MR, Alleva R, Moretti S, Andera L, Neuzil J, et al. α-Tocopheryl succinate and TRAIL selectively synergise in induction of apoptosis in human alignant mesothelioma cells. Br J Cancer 2004;90:1644-53.
15. Wang XF, Birringer M, Dong LF, Veprek P, Low P, Swettenham E, et al. A peptide conjugate of vitamin E succinate targets breast cancer cells with high erbB2 expression. Cancer Res 2007;67:3337-44.
16. Dalen H, Neuzil J. α-Tocopheryl succinate sensitises T lymphoma cells to TRAIL killing by suppressing NF-κB activation. Br J Cancer 2003;88:153-8.
17. Weber T, Dalen H, Andera L, Nègre-Salvayre A, Augé N, Sticha M, et al. Mitochondria play a central role in apoptosis induced by α-tocopheryl succinate, an agent with anticancer activity: comparison with receptormediated pro-apoptotic signaling. Biochemistry 2003;42:4277-91.
18. Holcik M. The IAP proteins. Trends Genet 2002;18:537-8.
19. Kataoka T, Budd RC, Holler N, Thome M, Martinon F, Irmler M, et al. The caspase-8 inhibitor FLIP promotes activation of NF kappaB and Erk signaling pathway. Curr Biol 2000;10:640-8.
20. Mathiasen IS, Lademann U, Jäättelä M. Cancer Res 1999;59:4848-56.
21. Liu N, Zhang J, Zhang J, Liu S, Liu Y, Zheng D. Erbin-regulated sensitivity of MCF-7 breast cancer cells to TRAIL via ErbB2/AKT/NF-kappaB pathway. J Biochem 2008;143:793-801.
22. Akazawa A, Nishikawa K, Suzuki K, Asano R, Kumadaki I, Satoh H, et al. Induction of apoptosis in a human breast cancer cell overexpressing ErbB-2 receptor by α-tocopheryloxybutyric acid. Jpn J Pharmacol 2002;89:417-21.
23. Erl W, Weber C, Wardemann C, Weber PC. α-Tocopheryl succinate inhibits monocytic cell adhesion to endothelial cells by suppressing NF-κB mobilization. Am J Physiol 1997;273: H634-40.
24. Bonavida B, Ng CP, Jazirehi A, Schiller G, Mizutani Y. Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: the trail to nontoxic cancer therapeutics. Int J Oncol 1999;15:793-802.
25. French LE, Tschopp J. The TRAIL to selective tumor death. Nat Med 1999;5:146-7.
26. Zou H, Li Y, Liu X, Wang X. An APAF-1·cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem 1999;274:11549-56.
27. Trauzold A, Schniewind B, Egberts J. TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene 2006;25:7434-9.
28. Weber T, Lu M, Andera L, Lahm H, Gellert N, Fariss MW, et al. Vitamin e succinate is a potent novel antineoplastic agent with high tumor selectivity and cooperativity with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL, Apo2L) in vivo. Clin Cancer Res 2002;8:863-9.
29. Wang XF, Dong LF, Zhao Y, Tomasetti M, Wu K, Neuzil J. Vitamin E analogues as anti-cancer agents: lessons from studies with α-tocopheryl succinate. Mol Nutr Food Res 2006;50:675-85.